Contact Us marketing@medicilon.com
CN
×
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
News and Events

Featured Stories

Hot information:
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Aug 26,2015
Researchers Successfully Reprogram Cancer Cells Back to Benign Cells by Debugging Microprocessor
Cancer is the fiercest disease to human. Scientists always look for the way to fight cancer. We have a good news after a lot of research and testing as Mayo Clinic researchers have discovered an unexpected connection between microRNA processing and cell-to-cell adhesion. This connection, the researchers maintain, not only explains the seemingly incongruous presenceRead more
More
Aug 26,2015
FDA expands use of Novartis' Promacta
US regulators have further extended the reach of Ligand/Novartis' Promacta, allowing its use to treat low blood platelet count in children – aged one year and older – with the rare blood disorder chronic immune thrombocytopenic purpura. Physicians can now prescribe the drug in paediatric patients when they have not achieved an appropriate response usingRead more
More
Aug 26,2015
Medicilon’s drug safety evaluation service successfully passed the CFDA review again
Last week, Medicilon's pre-clinical drug safety evaluation service passed the CFDA inspection again. This time, the two Shanghai biopharmaceutical companies that have long-term cooperation with Medicilon passed the inspection.
More
Medicilon’s drug safety evaluation service successfully passed the CFDA review again
Aug 25,2015
Cytovance Biologics was acquired by Hepalink USA for $205.68M
    Cytovance® Biologics, biopharmaceutical contract development manufacturing organization, will be acquired by Hepalink USA, the wholly owned U.S. subsidiary of Shenzhen Hepalink Pharmaceutical for $205.68 million cash plus additional contingent payments, Cytovance said.       The deal adds a CDMO to Hepalink's U.S. portfolio, which includes Scientific Protein Laboratories (SPL), a global supplier of active pharmaceutical ingredientsRead more
More
Aug 25,2015
How DNA Proofreader Proteins MutS and MutL Work?
    Two important proofreader proteins were discovered by scientists from North Carolina State University and the University of North Carolina at Chapel Hill.  The proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.     During DNA replication, the nucleotides are a correct match mostRead more
More
Aug 24,2015
Beige Fat Implantation Could Increase the Body Heat and Reduce the Weight Gain
    Fat in our body does not always harmful to us.  It does a better job of turning up the metabolic heat, and lessening the risks associated with obesity and diabetes, if it has a favorable balance of energy-storing fat and energy-burning fat. If that favorable balance doesn't exist naturally, it can be engineered, a newRead more
More
Aug 24,2015
Precision Medicine Get a Positive Result on Putting All Eggs in Basket Study
 Personalized medicine or PM is a medical model that proposes the customization of healthcare – with medical decisions, practices, and/or products being tailored to the individual patient.  One of the main goals of personalized medicine is the ability to quickly and accurately determine the genetic background of a patient and prescribe the appropriate therapy basedRead more
More
Precision Medicine Get a Positive Result on Putting All Eggs in Basket Study
Aug 21,2015
New Collaboration Form A New Company, Helix, to Allow Individuals Access on Their Genomes
    Collaboration is always the most efficient way to share the cost and the risk in the pharmaceutical industry.     Illumina, Warburg Pincus, and Sutter Hill Ventures set up a company with the goal of helping consumers discover insights into their own genomes. The new firm, Helix, is based in the San Francisco Bay Area and reportedRead more
More
Aug 21,2015
Transplanted Amniotic Stem Cells Offer Hope for Eye Diseases
Technology is ever-changing nowadays. The patients with retinal disease have new hope in the future as the South Korea scientists successfully transplanted the amniotic stem cells to human amniotic membranes into mice.
More
Aug 20,2015
Sanofi, Evotec and Apeiron Partner Together to Develop Immuno-Oncology Treatments
    The trends nowadays are the collaborations between different pharma companies.  This could help saving a lot of research time and cost.  Another giant pharma company from France, Sanofi, announced a research collaboration to focus on immuno-oncology treatment.     Sanofi said it has entered into a research collaboration with Evotec and Apeiron Biologics focused on developingRead more
More